Last reviewed 2026-04-23 · How we verify

FPA144

FPA144 is a monoclonal antibody that blocks fibroblast growth factor receptor 2b (FGFR2b) to inhibit tumor growth and angiogenesis.

FPA144 is a monoclonal antibody that blocks fibroblast growth factor receptor 2b (FGFR2b) to inhibit tumor growth and angiogenesis. Used for Gastric cancer and gastroesophageal junction cancer with FGFR2b overexpression.

At a glance

Mechanism of action

FPA144 selectively targets FGFR2b, a receptor involved in fibroblast growth factor signaling that promotes tumor cell proliferation and survival in certain cancers. By blocking this pathway, the drug aims to reduce tumor growth and inhibit the formation of new blood vessels that feed tumors. This mechanism is particularly relevant in gastric and gastroesophageal junction cancers that express high levels of FGFR2b.

Approved indications

• Gastric cancer and gastroesophageal junction cancer with FGFR2b overexpression

Common side effects

• Hyperphosphatemia
• Fatigue
• Nausea
• Diarrhea
• Decreased appetite

Key clinical trials

• Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors (PHASE1)
• A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (PHASE2)
• A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (PHASE1)
• A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer (PHASE1)
• An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.